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To determine the clinicopathologic characteristics of peripheral non-small- 
cell carcinomas, the cases of 337 patients undergoing major pulmonary 
resection with complete lymphadenectomy were retrospectively reviewed 
with regard to lymph node involvement, recurrence, and prognosis. All of 
the tumors were 3.0 cm or less in diameter and were categorized as T1 (318 
patients) or T2 (19). Eighty-eight patients (26.1%) had lymph node 
involvement: 32 (9.5%) at N1 nodes, 55 (16.3%) at N2 nodes, and 1 (0.3%) 
at N3 nodes. Although the prevalence of lymph node involvement did not 
differ significantly with tumor histologic type, it was quite low in squamous 
cell carcinomas 2.0 cm or less in diameter. Of the 56 N2/3 metastases, 14 
(25%) occurred in a "skipping" manner, and all but one had a nonsqua- 
mous histologic makeup. Of the 213 patients with a follow-up period of 5 
years or rr~ore, 59 patients (27.7%) showed cancer ecurrence. This occurred 
at a distant site in 67.8% of the cases. Five-year survival rates based on 
nodal status were 91.9% (NO), 61.8% (N1), 44.5% (N2), and 0% (N3). 
Because of the relatively high prevalence of lymph node involvement, 
complete hilar/mediastinal lymphadenectomy should be routinely done 
regardless of tumor histologic type and size, as long as patients are at good 
risk. However, in squamous cell histologic types, mediastinal lymphadenec- 
tomy might be dispensable if the tumor is less than 2.0 cm in diameter, or 
if the hilar node is proved to be tumor-free on pathologic examination ofthe 
frozen section during operation. Although video-assisted major pulmonary 
resection currently has limited application, this new technique may repre- 
sent a surgical option in resection without complete lymphadenectomy. 
(J Thorac Cardiovasc Surg 1996;111:1125-34) 
A mong thoracic surgeons, the operative strategy for small, peripheral ung carcinomas can be 
addressed through the following questions: What 
should the extent of resection be? 1-3 Should a 
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lymphadenectomy be done 4 and, if so, to what 
extent? 
Since the advent of video-assisted thoracic sur- 
gery (VATS), this new technique has been applied 
to a wide variety of thoracic operations, ' 6 In paren- 
chymal lung resection, surgeons face a variety of 
challenges ranging from simple wedge resection to 
more complicated major resections uch as lobec- 
tomy and pneumonectomy. 7 For lung carcinomas, 
however, there remains considerable controversy 
concerning the therapeutic role of VATS. Recently, 
the strategy for small, peripheral lung carcinomas 
has become more enthusiastically discussed in rela- 
tion to VATS, because these tumors without nodal 
involvement were regarded as possible candidates 
for this new procedure. In several recent reports 
dealing with VATS major pulmonary resections, the 
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Table I. Patient characteristics Table I I .  Lymph node location 
No. N2 node N1 node 
Gender 
Male 222 
Female 115 
Histologic type 
Adenocarcinoma 280 
Squamous cell carcinoma 44 
Large-cell carcinoma 10 
Adenosquamous carcinoma 3 
Tumor size 
-<1.0 cm 8 
>1.0 cm and -<2.0 cm 166 
>2.0 cm and -<3.0 cm 163 
Tumor status 
T1 318 
T2 19 
Node status 
N0 249 
N1 32 
N2 55 
N3 1 
Postoperative stage 
I 246 
II 31 
IIIA 50 
IIIB 1 
IV 9 
Tumor location by lobe 
Right upper lobe 122 
Right middle lobe 31 
Right lower lobe 64 
Left upper lobe 83 
Left lower lobe 37 
Operation mode 
Pneumonectomy 6 
Lobectomy 326 
Sleeve lobectomy 5 
definite indication for lung carcinomas was not 
clearly demonstrated,  s-a° To establish the surgical 
strategy for these tumors, it is important  o know 
their cl inicopathologic features. 
In this retrospective study, we intended to clarify 
the characteristics of these tumors with special 
emphasis on the lymph node involvement, he mode 
of recurrence, and survival, the former being closely 
related to the operat ive procedures.  
Material and methods 
We surgically treated 337 patients with primary lung 
carcinoma (maximum tumor diameter of 3.0 cm or less) 
between 1980 and 1993 at the National Cancer Center 
Hospital, Tokyo. The median follow-up period was 1465 
days. These tumors were all located at the periphery of the 
lung and were resected by either lobectomy or pneumo- 
nectomy combined with complete hilar and mediastinal 
lymphadenectomy. Five sleeve lobectomies and six pneu- 
Superior mediastinal 
No. 1. Highest mediastinal 
No. 2. Paratracheal 
No. 3. Pretracheal 
No. 4. Tracheobronchial angle 
Aortic 
No. 5. Botallo's 
No. 6. Para-aortic (ascending aorta) 
Inferior mediastinal 
No. 7. Subcarinal 
No. 8. Paraesophageal 
No. 9. Pulmonary ligament 
Hilar 
No. 10. Hilar 
No. 11. Interlobar 
No. 12. Lobar 
Intrapulmonary 
No. 13. Segmental 
No. 14. Subsegmental 
monectomies were done mainly for the purpose of erad- 
icating the swollen hilar nodes (around the main bronchus 
or between different lobes) adherent to the bronchial wall. 
During the same period, 1914 primary lung carcinomas 
were treated by resection to various extents and lymphad- 
enectomy. Therefore 337 patients comprised 17.6% of the 
total. The patients ranged in age from 26 to 85 years 
(mean age, 59.8 years). Two hundred twenty-two patients 
were male and 115 were female. Most of the patients 
underwent a physical examination, chest roentgenogra- 
phy, chest computed tomographic s an, bone scintigraphy, 
and abdominal ultrasonography for staging and evaluation 
of resectability before the operation. The clinical charac- 
teristics of the 337 patients are presented in Table I. 
Resected specimens were examined histologically, and 
their histologic type was determined according to the 
World Health Organization classification ~ as adenocar- 
cinoma, squamous cell carcinoma, large cell carcinoma, or 
adenosquamous carcinoma. The extent of lymph node 
spread was also recorded. The median number of lymph 
nodes resected and examined was 19 per patient (range, 6 
to 71). The locations of intrapulmonary (Nos. 13 and 14, 
N1), hilar (Nos. 10 through 12, N1), mediastinal (Nos. 1 
through 9, N2), and contralateral hilar (contralateral No. 
10, N3) lymph nodes were expressed according to the 
lymph node map for lung cancer proposed by one of us 
(T. N., Table II). 12 Mediastinal metastasis was considered 
"skipping" if any one of the mediastinal lymph nodes was 
involved by the tumor, without hilar or intrapulmonary node 
metastasis. The stage of the disease was based on the TNM 
classification of the Union Internationale Contre Cancer. 13 
Cancer recurrence was carefully divided according to 
the site of the initial relapse into two categories: locore- 
gional and distant recurrence. Locoregional recurrence 
was defined as any recurrent disease within the ipsilateral 
hemithorax, mediastinum, or supraclavicular lymph 
nodes. All other sites of recurrence were considered 
distant metastases. Second primary carcinoma of the lung 
was also documented, if the criteria proposed by Martini 
and Melamed TM were met; in brief, if the carcinoma was a 
different histologic type, the same histologic type with a 
disease-free interval more than 2 years, or without either 
common lymphatic involvement or extrapulmonary me- 
tastases. The cause of death was recorded as either 
cancer-related, other disease, or unknown. Survival rate 
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Table III. Preoperative and postoperative diagnosis 
of lymph node metastasis 
Postop. node diagnosis 
Preop. node diagnosis NO N1 N2 N3 Total 
NO 237 24 43 1 305 
N1 5 5 8 18 
N2 7 3 4 14 
Total 249 32 55 1 337 
Table IV. Lymph node involvement according to 
tumor diameter 
Nodal status 
T~mor 
diameter (cm) NO N1 N2 N3 Total 
-<2.0 
>2.0 and -<3.0 
Total 
140 (80.5) 14 (8.0) 20 (11.5) 0 (0.0) 174 (100) 
10 (66.9) 18 (11.0) 35 (21.5) 1 (0.6) 163 (100) 
249 (73.9) 32 (9.5) 55 (16.3) 1 (0.3) 337 (100) 
Numbers in parentheses indicate percentage. Statistically significant 
(X 2 test, p - 0.028). 
was calculated by the Kaplan-Meier life-table method 15 
and compared by a log rank test 16 in which the initial day 
of treatment was the day of operation. Cases with death 
that was not caused by cancer were considered censored. 
A X 2 test was used to compare the various rates, and p < 
0.05 was considered statistically significant. 
Patients with the following tumors or conditions were 
excluded from this study: (1) tumors with small-cell or 
low-grade malignant histologic makeup; (2) hilar tumors; 
(3) T3 or T4 tumors including those with malignant 
effusion and pleural dissemination; (4) tumors with distant 
metastasis; (5) operation with less than lobectomy for 
primary tumor; and (6) operation without hilar and me- 
diastinal lymphadenectomy. 
Carcinomas with minute, satellite nodules that were found 
incidentally within the same lobe of the resected specimen 
were not excluded from the study, because itwas not certain 
whether these lesions should be considered local tumor 
spread or hematogenous spread (distant metastasis). How- 
ever, these lesions were categorized as M1. Tumors with 
minute lesions within another lobe were excluded. 
Results 
Lymph node involvement. Lymph node involve- 
ment was recognized in 88 (26.1%) of the 337 
patients: in 1 patient (0.3%) at the contralateral 
hilum, in 55 (16.3%) at the mediastinum, and in 32 
(9.5%) at the hilum or within the lung. The distri- 
bution of preoperative and postoperative nodal sta- 
tus is shown in Table III. Lymph node involvement 
was compared in terms of tumor diameter and 
histologic type. Lymph node metastasis at the me- 
diastinum and pulmonary hilum was significantly 
more common in tumors more than 2.0 cm in 
diameter (32.5%) than in those 2.0 cm or less in 
Table V. Lymph node involvement according to 
tumor histologic type 
Nodal status 
Histologic type NO N1 N2 N3 Total 
Adenocarcinoma 203 (72.5) 28 (10.0) 48 (17.1) 1 (0.4) 280 (100) 
Squamous cell 38 (86.3) 1 (2.3) 5 (11.4) 0 44 (100) 
carcinoma 
Large cell 7 (70.0) 1 (10.0) 2 (20.0) 0 10 (100) 
carcinoma 
Adenosquamous 1 (33.3) 2 (66.7) 0 0 3 (100) 
carcinoma 
Total 249 (73.9) 32 (9.5) 55 (16.3) 1 (0.3) 337 (100) 
Numbers in parentheses indicate percentage. 
Table VI. Lymph node involvement of 174 patients 
with tumors 2. 0 cm or less in diameter according to 
tumor histologic type 
Nodal status 
Histologic type NO N1 N2 Total 
Adenocarcinoma 120 (78.9) 13 (8.6) 19 (12.5) 152 (100) 
Squamous cell 15 (93.7) 0 (0.0) 1 (6.3) 16 (100) 
carcinoma 
Large cell 5 (83.3) 1 (16.7) 0 (0.0) 6 (100) 
carcinoma 
Adenosquamous 0 0 0 0 
carcinoma 
Total 140 (80.5) 14 (8.0) 20 (11.5) 174 (100) 
Numbers in parentheses indicate percentage. 
diameter (19.5%) (p = 0.028, )(2 test, Table IV). 
However, there was no significant difference on the 
basis of tumor histologic type, even though patients 
with N2/3 disease more frequently had adenocarci- 
noma than squamous cell carcinoma (17.5% versus 
11.4%, respectively, Table V). Lymph node involve- 
ment was also analyzed by histologic type in 174 
patients with tumors 2.0 cm or less in diameter 
(Table VI). In this subgroup of patients, there was 
also no difference in the incidence of N2/3 metasta- 
sis according to histologic type. 
Involvement of the mediastinal (Table VII) and 
hilar/intrapulmonary (Table VIII) nodes was analyzed 
in terms of the location of the primary tumors. The 
most frequent site of metastasis n the mediastinum 
differed according to the location of the primary 
tumor: on the right side, the pretracheal (No. 3) nodes 
were the most common site of spread in tumors of 
upper and middle lobes, whereas the subcarinal (No. 
7) nodes were the most common site of spread in 
tumors of middle and lower lobes. On the left side, the 
tracheobronchial (No. 4), Botallo's (No. 5), and para- 
aortic (No. 6) nodes were mainly involved in tumors of 
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Table VII. Lymph node involvement to the mediastinum according to tumor location 
Mediastinal lymph node location 
Location No. 1 No. 2 No. 3 No. 4 No. 5 No. 6 No. 7 No. 8 No. 9 N2/3 
RUL (122) 5 (4.1) 3 (2.5) 17 (13.9) 4 (3.3) 2 (1.6) 18 (14.8) 
RML (31) 2 (6.5) 1 (3.2) 5 (16.1) 5 (16.1) 7 (22.6) 
RLL (64) 3 (4.7) 3 (4.7) 8 (12.5) 2 (3.1) 11 (17.2) 
LUL (83) 3 (3.6) 2 (2.4) 6 (7.2) 5 (6.0) 6 (7.2) 4 (4.8) 15 (18.1) 
LLL (37) 1 (2.7) 1 (2.7) 1 (2.7) 3 (8.1) 1 (2.7) 1 (2.7) 5 (13.5) 
Numbers in parentheses indicate percentage. RUL, Right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower 
lobe. 
Table VIII. Lymph node involvement to the hilum and lung according to tumor location 
Hilar intrapulmonary lymph node location 
Location No. 10 No. 11 No. 12 No. 13 No. 14 NI* 
RUL (122) 5 (4.1) 8 (6.6) 9 (7.4) 8 (6.6) 3 (2.5) 22 (18.0) 
RML (31) 3 (9.7) 6 (19.4) 3 (9.7) 1 (3.2) 1 (3.2) 9 (29.0) 
RLL (64) 4 (6.3) 9 (14.1) 6 (9.4) 4 (6.3) 1 (1.6) 24 (37.5) 
LUL (83) 7 (8.4) 6 (7.2) 11 (13.3) 7 (8.4) 4 (4.8) 23 (27.7) 
LLL (37) 1 (2.7) 2 (5.4) 3 (8.1) 2 (5.4) 1 (2.7) 6 (16.2) 
Numbers in parentheses indicate percentage. RUL, Right upper lobe; RML, right middle lobe; RLL, right 
lobe. 
*Patients with both mediastinal and hilar/intrapulmonary metastases were included. 
lower lobe; LUL, left upper lobe; LLL, left lower 
Table IX. Characteristics of 14 patients with 
skipping metastases 
Primary lesion No. f Metastatic site Histologic type 
( lobe) patients (No.) (No.) 
RUL 
RML 
RLL 
LUL 
LLL 
Total 
6 No. 3 (6) AD (5), LG (1) 
No. 1 (1) 
3 No. 3 (2) AD (3) 
No. 2 (1) 
No. 7 (1) 
1 No. 7 (1) AD (1) 
3 No. 6 (2) AD (2), SQ (1) 
No. 5 (1) 
No. 7 (1) 
1 No. 7 (1) AD (1) 
14 
AD, Adenocarcinoma; LG, large cell carcinoma; SQ, squamous cell 
carcinoma; RUL, right upper lobe; RML, right middle lobe; RLL, right 
lower lobe; LUL, left upper lobe; LLL, left lower lobe. 
the upper lobe, whereas the subcarinal (No. 7) nodes 
were involved in tumors of the lower lobe. 
Skipping metastases (Table IX). Of the 56 cases 
of N2/N3 disease, 14 were skipping metastases 
(25%). Histologically, 12 of the 14 skipping metas- 
tases occurred in adenocarcinomas and one each 
occurred in large cell carcinoma and squamous cell 
carcinoma. On the right side, the most common site 
of involvement of skipping metastasis was the pre- 
tracheal (No. 3) nodes in eight patients, followed by 
the subcarinal (No. 7) nodes in two and by nodes 
Nos. 1 and 2 in one patient each. The pretracheal 
node was involved only in tumors of the right upper 
and middle lobes and not in tumors of the lower 
lobe. On the left side, the para-aortic (No. 6) and 
Botallo's (No. 5) nodes were involved only in tumors 
of the upper lobe, whereas the subcarinal (No. 7) 
nodes were involved in tumors of both lobes, al- 
though the number of patients was limited. 
M1 disease. Nine patients had minute carcino- 
matous nodules incidentally found in the same lobe 
as the main tumor at the time of pathologic exami- 
nation. These nodules were apparently remote from 
the main lesion and only a few millimeters in 
diameter. We categorized these carcinomatous le- 
sions as M1 disease. The nodal status of the nine 
patients was as follows: NO in three, N1 in one, and 
N2 in five. Four of them had recurrence (2 locore- 
gional, 2 distant). All of the patients with recurrence 
died of cancer. The remaining five patients re- 
mained alive without disease. 
Recurrence. Cancer recurrence was analyzed 
only for 213 patients who were operated on 5 or 
more years previously. Fifty-nine patients (27.7%) 
showed cancer recurrence, 7 showed second primary 
lung carcinoma after operation, and 4 were lost to 
follow-up. Among the patients with recurrence, 40 
(67.8%) had istant relapse, 17 (28.8%) had locore- 
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Table X. First relapse site in patients with cancer 
recurrence in 213 patients with a follow-up eriod of 
5 years or more 
No. 
Locoregional 19 
Supraclavicular lymph node 10 
Lung 4 
Bronchial stump 2 
Pleural effusion 2 
Mediastinal lymph node 1 
Distant 42 
Lung 14 
Bone 13 
Brain 6 
Liver 3 
Adrenal gland 1 
Miscellaneous 5 
Table XI. Cancer recurrence according to tumor 
histologic type in 213 pdtients with a follow-up 
period of 5 years or more 
With Without 
Histologic type recurrence recurrence Total 
Adenocarcinoma 53 (31.9) 113 (68.1) 166 (100) 
Squamous cell carcinoma 2 (7.7) 24 (92.3) 26 (100) 
Large cell carcinoma 2 (28.6) 5 (71.4) 7 (!00) 
Adenosquamous carcinoma 2 (66.7) 1 (33.3) 3 (100) 
Total 59 (29.2) 143 (70.8) 202 (100) 
The numbers in parentheses indicate percentage. Statistically significant 
0~, P = 0.0375). 
gional relapse, and two (3.4%) had both simulta- 
neously. The initial site of recurrence ispresented in
Table X. The intervals from the initial operation to 
the discovery of recurrence varied from 83 to 2978 
days. In 11 cases (5.2%), recurrence was found 5 
years or more after resection of the primary tumor: 
These were all adenocarcinomas. Table XI shows 
the prevalence of recurrence according to histologic 
type; adenocarcinoma had a significantly higher 
prevalence of recurrence compared with the other 
histologic types 0( 2 test, p = 0.0375). In Table XII, 
the prevalence of recurrence is shown according to 
histologic type for patients with resected stage I 
disease. In this smaller category, there was no 
significant difference between the different histo- 
logic types (X2~ test, p = 0.3095). 
Prognosis. The survival curve for all 337 patients i
shown in Fig. 1. The 5- and 10-year survival rates were 
77.2% and 59.5%, respectively. Survival curves were 
drawn according to nodal status (Fig. 2). As shown in 
Table XIII, significant differences were found among 
the 5- and 10-year survival rates in each nodal category 
Table XII. Cancer recurrence in stage I disease 
according to histologic type 
With Without 
Histologic type recurrence recurrence Total 
Adenocarcinoma 24 (19.8) 97 (80.2) 121 i100) 
Squamous Cell carcinoma 1 (4.3) 22 (95.7) 23 (100) 
Large cell carcinoma 1 (25) 3 (75) 4 (100) 
Adenosquarnous carcinoma 0 (0) 1 (100) 1 (100) 
Total 26 (17.4) 123 (82.6) 149 (100) 
The numbers inparentheses indicate percentage. 
Table XIII. Survival rates based on nodal status 
(percent) 
Nodal status 
Survival NO N1 N2 N3 
5-Year survival 91.9 61.8 44.5 0.0 
10-Year survival 86.9 27.5 0.0 0.0 
(p < 0.0001). Survival curves of patients with and 
without lymph node involvement are shown according 
to histologic type in Figs. 3 and 4, respectively. There 
was no statistically significant difference in survival 
between the different histologic types. 
Survival was further compared in patients with and 
without lymph node involvement acdording to tumor 
diameter: tumors 2.0 cm or less in diameter and those 
more than 2.0 cm in diameter (Figs. 5 and 6). NO 
significant difference was seen in survival accord- 
ing to tumor diameter. In the 56 patient s with 
N2/3 disease, the prognosis of patients with lymph 
node involvement in only one mediastinal lymph 
node location was compared with the prognosis in 
those with lymph node involvement in two or 
more locations. Patients in whom only one loca- 
tion was involved showed no survival advantage. 
Discussion 
One of the important findings in the current study 
was the relatively high prevalence of lymph node 
involvement despite the small size of the primary 
tumor: 26.1% in tumors 3.0 cm or less in diameter and 
19.5% in those 2.0 cm or Smaller. However, several 
points were also of clinical interest. First, larger tumors 
were associated with a significantly higher prevalence 
of lymph node involvement. Second, with regard to 
lymph node involvement, here was no significant 
difference between adenocarcinomas nd squamous 
cell carcinomas both originating at the periphery, 
although the latter have been reported to grow more 
locally. 17 This observation i dicated that even squa- 
1130 Asamura et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
June 1996 
@ 
. - -  
100- -  
i 
50 --  
0 
0 
I m - -  mL . - -~  
~ ~' I :~..L i ,~a , ,  l i  I , ~ , ,  , , :  
i 
I I I I I 
1 2 3 4 5 
Surv iva l  t ime (year )  
Fig. I. Survival curve for all 337 patients with lung carcinoma 3.0 cm or less in diameter. 
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Fig. 2, Survival curves based on nodal status (NO, N1, N2/3). Statistically significant difference was 
observed (log-rank test, p < 0.0001). 
mous cell carcinomas, if they originate at the periph- 
eral lung, might have clinical characteristics similar to 
those of adenocarcinomas arising at the same location, 
which may account for the cytopathologic similarities 
of these two histoiogic types.17 However, the difference 
in the tendency to lymph node involvement between 
the two histologic types might become clearer if a large 
enough number of patients with squamous cell carci- 
noma is studied. 
A third point of clinical interest is that lymph node 
involvement was very rare among squamous cell car- 
cinomas 2.0 cm or less in diameter. This rarity of 
lymphatic spread might justify not performing lymph- 
adenectomy. Fourth, the location of the involved 
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lymph node was determined primarily by the lo.be in 
which the primary tumor was located. Especially on 
the right side, this rule was clear. This was probably 
because the metastasis occurred in the direction of the 
lymphatic stream. Only the middle lobe had two 
mediastinal locations in favor of lymph node involve- 
ment (Nos. 3 and 7), which indicates that the middle 
lobe has the two major lymphatic drainage pathways 
common for both the upper and lower lobes. 
Skipping metastasis also has considerable clinical 
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significance when we weigh strategies for lymphad- 
enectomy in such small-sized carcinomas. In our 
series, 25% of N2 involvement occurred in a skip- 
ping manner (mediastinal involvement without hilar 
involvement). This rate is close to those reported 
previously: 27% by Martini and colleagues, ts 28.6% 
by lshida and colleagues, 19and 31.5% by Naruke. 2° 
Two points were of clinical significance: (1) this 
"skipping" spread occurred almost exclusively in 
adenocarcinomas nd (2) a special ocation of the 
lymph nodes was affected in the skipping involve- 
ment. and this was determined by the. location of the 
primary tumor. For example, in tumors of the right 
upper lobe, skipping involvement occurred exclu- 
sively in the upper mediastinum. Therefore we 
should not overlook the sampling or dissection of 
such "sentinel" nodes, even for staging. 
Another important finding was the better survival 
in the current series compared with those in previ- 
ous series, including our own. Especially for re- 
sected T1 NO M0 tumors, whereas the previously 
reported 5-year survival rate has ranged from 70% 
to 83%, 21-24 the present series showed a survival rate 
of 92.6%. Although squamous cell carcinoma of 
hilar origin was not included in the present series, 
this may not have significantly affected the results, 
because this group also showed a good prognosis. 
The most probable explanation for the b tter sur- 
viva! in the present series might involve patient 
selection, because all of the patients underwent 
complete lymphadenectomy and were categorized 
according to subsequent pathologic examination. T1 
NO tumors, which were diagnosed by operative 
palpation alone without mediastinal dissection or by 
sampling only a limited number or location of 
nodes, were all excluded from the present series. 
These might inevitably include more advanced la- 
tent or subclinical N2 diseases. The better ~linical 
outcome might be a result of the exclusion of 
aberrant advanced isease and of the purification of 
each TNM category. Our results may reflect prog- 
nQstic data based on the most purified T1 NO M0 
po.pulation, which indicates the importance of accurate 
staging by complete lymphadenectomy. However, the 
prognostic impact of this factor could not be clearly 
determined in the setting of the current study. 
Cancer recurrence after resection, especially for 
resected stage I disease, has been analyzed in sev- 
eral previous reports with different comments. In 
the current series, there was no significant histologic 
propensity for cancer recurrence in potients with 
stage I disease, although adenocarcinoma showed a 
significantly higher recurrence rate in the entire 
group. Pairolero and associates 25also demons, trated 
that there was no significant difference in the overall 
rate of recurrence among the various cell types. On 
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Fig. 6. Survival curves based on tumor diameter in patients with lymph node involvement. There was no 
statistically significant difference (log-rank test, p = 0.1121). 
the other hand, a significantly higher rate of recur- 
rence was found for those with nonsquamous histo- 
logic makeup, compared with squamous histologic 
makeup, in a series of studies by the Lung Cancer 
Study Group. 26' 27 Because we excluded squamous cell 
carcinoma of hilar origin, the locoregional recurrence 
rate may have been reduced. However, it should be 
remembered that peripheral squamous cell carcinoma 
has a tendency for recurrence similar to that of periph- 
eral adenocarcinoma. In terms of the first relapse site, 
all of the previous reports have recognized a common 
site of recurrence at distant organs for 56% to 75% of 
all instances of recurrence. 25' 27 
What, then, should the surgical strategy for small, 
peripheral ung carcinomas be? Concerning the 
extent of resection for the primary tumor, a random- 
ized study by the Lung Cancer Study Group in T1 
NO carcinomas has provided at least one answer. 2' 3 
Both a threefold increase in locoregional failure and 
a small but significant reduction in survival in the 
limited resection group favored lobectomy. For sys- 
tematic mediastinal lymphadenectomy, a random- 
ized trial by Izbicki and colleagues 4 showed no 
survival benefit. The current results, however, still 
favor lymphadenectomy of the hilum and mediasti- 
hum, regardless of histologic type, because of the 
high prevalence of lymph node involvement in tu- 
mors 3.0 cm or less in diameter, with a goal of 
accurate staging and possible cure. Lymphadenec- 
tomy to a smaller extent might be an option for 
patients with squamous cell carcinomas with a di- 
ameter 2.0 cm or less, inasmuch as lymph node 
involvement was rare in these tumors. Furthermore, 
because of the rarity of skipping metastasis n squa- 
mous cell carcinoma, if the hilar node is free from 
tumor cells in a frozen section during the operation, 
mediastinal lymphadenectomy ight not be neces- 
sary. In nonsquamous carcinoma, we still support 
the need for lymphadenectomy and recommend that 
the extent of the dissection ot be minimized. 
The current results address whether small, pe- 
ripheral ung carcinomas are candidates for VATS. 
Definite indications for major VATS in lung cancer 
have not yet been determined. Roviaro and associ- 
ates 8 reported that a "small peripheral esion in 
stage I" might be a candidate for VATS. Lewis 1° 
reported a strategy in which wedge or sublobar 
resection was done in tumors 2.0 cm or less in 
diameter, whereas lobectomy was done in larger 
tumors and those located more deeply. In the report 
by Kirby and Rice, 9 lobectomies were done for stage 
I non-small-cell carcinoma in patients with good risk 
conditions because of their "pilot study" setting. 
However, are major pulmonary resection and 
lymphadenectomy technically feasible? Reports by 
other groups and our own experiences have shown 
that VATS lobectomy can be done under conditions 
of good lobulation, minimal adhesion, minimal an- 
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atomic anomaly, and good cardiopulmonary func- 
tion that will allow one-lung ventilation. A detailed 
description of video-assisted lymphadenectomy has
not yet been reported. Our experience with open 
thoracotomy, however, suggests that lymphadenec- 
tomy can be difficult, particularly in nodes at he 
special ocations uch as the hilum and subcarina 
(No. 7); the latter requires considerable retraction. 
Therefore we should realize that because the surgi- 
cal technique for complete video-assisted lymphad- 
enectomy has not yet been established, it is unlikely 
that it is done as it is done with open thoracotomy. 
In conclusion, we think the basic strategy for 
lymphadenectomy in patients with small, peripheral 
non-small-cell carcinomas should be as follows. 
1. Complete hilar/mediastinal lymphadenectomy 
should be routinely done regardless of tumor 
histologic type as long as patients are at good risk 
and are thought to be able to tolerate this 
surgical procedure. 
2. In squamous cell histologic types, the prevalence 
of nodal involvement was low in tumors 2.0 cm or 
less in diameter. Mediastinal nodal involvement 
was also less common, if the hilar node was free 
from carcinoma cells. Therefore mediastinal lymph- 
adenectomy might be dispensable, if the tumor is 
less than 2.0 cm in diameter or if the hilar node is 
proved to be tumor-free on pathologic examination 
of the frozen section during operation. 
Considering the technical limitations of the cur- 
rent VATS procedures, especially in the perfor- 
mance of meticulous lymphadenectomy, we think 
that the present results uggest that performance of
VATS lobectomy with less than complete lymphad- 
enectomy would not be recommended, even if the 
tumors are T1. Furthermore, because cN0 status in 
43 of 305 patients was converted to pN2 after 
operation, evaluation by preoperative mediastinos- 
copy is strongly recommended for the better selec- 
tion of future VATS candidates. 
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